Kevin Achberger; Christopher Probst; Jasmin Haderspeck; Sylvia Bolz; Julia Rogal; Johanna Chuchuy; Marina Nikolova; Virginia Cora; Lena Antkowiak; Wadood Haq; Nian Shen; Katja Schenke‐Layland; Marius Ueffing; Stefan Liebau; Peter Loskill · 2019 · eLife
Paper
The devastating effects and incurable nature of hereditary and sporadic retinal diseases such as Stargardt disease, age-related macular degeneration or retinitis pigmentosa urgently require the development of new therapeutic strategies. Additionally, a high prevalence of retinal toxicities is becoming more and more an issue of novel targeted therapeutic agents. Ophthalmologic drug development, to date, largely relies on animal models, which often do not provide results that are translatable to human patients. Hence, the establishment of sophisticated human tissue-based in vitro models is of upmost importance. The discovery of self-forming retinal organoids (ROs) derived from human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs) is a promising approach to model the complex stratified retinal tissue. Yet, ROs lack vascularization and cannot recapitulate the important physiological interactions of matured photoreceptors and the retinal pigment epithelium (RPE). In this study, we present the retina-on-a-chip (RoC), a novel microphysiological model of the human retina integrating more than seven different essential retinal cell types derived from hiPSCs. It provides vasculature-like perfusion and enables, for the first time, the recapitulation of the interaction of mature photoreceptor segments with RPE in vitro. We show that this interaction enhances the formation of outer segment-like structures and the establishment of in vivo-like physiological processes such as outer segment phagocytosis and calcium dynamics. In addition, we demonstrate the applicability of the RoC for drug testing, by reproducing the retinopathic side-effects of the anti-malaria drug chloroquine and the antibiotic gentamicin. The developed hiPSC-based RoC has the potential to promote drug development and provide new insights into the underlying pathology of retinal diseases.
Analysis
This study presents a novel human retina-on-a-chip (RoC) platform that integrates multiple retinal cell types and vasculature-like perfusion to model complex retinal physiology and disease.
Discovery
Mark T. Kozlowski; Christiana Crook; Hsun Teresa Ku
Fuyin Zheng; Yuminghao Xiao; Hui Liu; Yubo Fan; Ming Dao
Caleb Jensen; Yong Teng
Qirui Wu; Jinfeng Liu; Xiaohong Wang; Lingyan Feng; Jinbo Wu; Xiaoli Zhu; Weijia Wen; Xiuqing Gong
Giovanni Giuseppe Giobbe; Claire Crowley; Camilla Luni; Sara Campinoti; Moustafa Khedr; Kai Kretzschmar; Martina M. De Santis; Elisa Zambaiti; Federica Michielin; Laween Meran; Qianjiang Hu; Gijs J. F. van Son; Luca Urbani; Manfredi Anna; Monica Giomo; Simon Eaton; Davide Cacchiarelli; Vivian Li; Hans Clevers; Paola Bonfanti; Nicola Elvassore; Paolo De Coppi
Ruoshi Shi; Nikolina Radulovich; Christine Ng; Geoffrey Liu; Hirotsugu Notsuda; Michael Cabanero; Sebastião N. Martins-Filho; Vibha Raghavan; Quan Li; Arvind Singh Mer; Joshua C. Rosen; Ming Li; Yu-Hui Wang; Laura Tamblyn; Nhu‐An Pham; Benjamin Haibe‐Kains; Geoffrey Liu; Nadeem Moghal; Ming‐Sound Tsao
Source record